Auckland Cancer Society Research Centre

Experimental Therapeutics Group

Group leader

Principal investigators


The research of the Experimental Therapeutics Group (ETG) focuses on the discovery and development of novel small molecule anticancer drugs, with interests spanning all aspects of the drug development pipeline from target validation to early phase clinical trials. Our main emphasis is on exploiting abnormalities in the tumour microenvironment, such as hypoxia, that arise because of an inefficient vascular supply. A major interest is the development of prodrugs that are activated locally within tumours, either through metabolism by endogenous enzymes under hypoxia or through the introduction of exogenous drug-metabolising enzymes. Our drug discovery projects are in collaboration with the Medicinal Chemistry Group. The ETG also has a strong interest in the diffusion of anticancer agents and their active metabolites in tumour tissue, which is an important and neglected problem in cancer pharmacology.

Medicinal Chemistry Group